CN113549066B - Crystal forms of dihydronaphthyridine compounds and application thereof - Google Patents
Crystal forms of dihydronaphthyridine compounds and application thereof Download PDFInfo
- Publication number
- CN113549066B CN113549066B CN202110440945.5A CN202110440945A CN113549066B CN 113549066 B CN113549066 B CN 113549066B CN 202110440945 A CN202110440945 A CN 202110440945A CN 113549066 B CN113549066 B CN 113549066B
- Authority
- CN
- China
- Prior art keywords
- ray powder
- powder diffraction
- crystalline
- compound
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a crystal form of a dihydronaphthyridine compound and application thereof. The invention also relates to a pharmaceutical composition containing the crystal form, and application of the crystal form or the pharmaceutical composition in preparing medicines for treating and preventing diseases such as hyperaldosteronism, diabetic nephropathy, hypertension, heart failure (including chronic heart failure and the like), sequelae of myocardial infarction, liver cirrhosis, renal failure, stroke and the like.
Description
Technical Field
The invention belongs to the technical field of medicines, relates to a crystal form of a dihydronaphthyridine compound and application thereof, in particular to a stereoisomer of 4- (4-cyano-2-methoxyphenyl) -5-cyclobutyloxy-2, 8-dimethyl-1, 4-dihydro-1, 6-naphthyridine-3-carboxamide and the crystal form and application thereof, and further relates to a pharmaceutical composition containing the crystal form.
Background
Mineralocorticoid receptors (Mineralocorticoid Receptor, MR) are aldosterone-activated nuclear hormone receptors that regulate the expression of a number of genes involved in electrolyte homeostasis and cardiovascular disease. The increase in circulating aldosterone increases blood pressure through its effect on natriuresis, while potentially affecting the brain, heart and vascular system. In addition, hyperaldosteronism is associated with a number of disease physiological processes leading to renal and cardiovascular disease. Although hyperaldosteronism is often caused by adenomas that produce aldosterone, the aldosterone levels in patients with refractory hypertension are often elevated, often referred to as "aldosterone escape", due to elevated serum potassium levels or residual AT1R activity. Aldosterone excess and aldosterone escape typically result in increased MR activity, and MR antagonists have been shown to be effective antihypertensives and also effective in the treatment of heart failure and primary aldosterone excess. In addition, MR antagonists have also proven to be effective in preclinical models of kidney disease, and can be used in combination with standard therapies to reduce proteinuria in patients with kidney disease, such as chronic kidney disease, including diabetic nephropathy.
International application WO 2019223629 A1 discloses dihydropyrimidine compounds, wherein the compounds have a Mineralocorticoid Receptor (MR) antagonism and can be used for treating and preventing hyperaldosteronism, diabetic nephropathy, hypertension, heart failure (including chronic heart failure and the like), sequelae of myocardial infarction, cirrhosis, renal failure, stroke and other diseases. Specifically, this patent application discloses the compound 4- (4-cyano-2-methoxyphenyl) -5-cyclobutyloxy-2, 8-dimethyl-1, 4-dihydro-1, 6-naphthyridine-3-carboxamide (compound of formula (Ia)) and stereoisomers thereof, but there is no study and report in the prior art about the crystalline form of this compound or its stereoconfiguration.
Drug polymorphism is a common phenomenon in drug development and is an important factor affecting drug quality. Different crystal forms of the same medicine may have obvious differences in appearance, solubility, melting point, dissolution rate, bioavailability and the like, and also have different effects on the aspects of stability, bioavailability, curative effect and the like of the medicine. Therefore, the problem of polymorphism of the drug should be comprehensively considered in drug development.
Disclosure of Invention
The prior art WO 2019223629 A1 discloses compounds of formula (Ia) and a process for their preparation, while giving stereoisomers thereof, i.e. compounds of formula (I) according to the invention. The invention provides a preparation method of the stereoisomer, and also provides a crystal form or an amorphous form of the stereoisomer, wherein the crystal form, particularly the crystal form I, can obviously improve the stability, pharmacokinetics and other properties of the compound, thereby having better patentability.
In particular, the invention relates to a compound shown in a formula (I) and a crystal form or an amorphous form thereof, and the use of the crystal form or the amorphous form of the compound or a pharmaceutical composition containing the crystal form or the amorphous form as a mineralocorticoid antagonist and/or the use of the compound or the amorphous form or the pharmaceutical composition containing the crystal form or the amorphous form as a mineralocorticoid antagonist in preparation of a medicament for treating or preventing diseases related to mineralocorticoid. The crystalline forms of the invention may also be in the form of solvates, for example hydrates.
In one aspect, the present invention provides a compound of formula (I):
in another aspect, the present invention provides a crystalline form of a compound of formula (I),
in some embodiments, the crystalline form of the compound of formula (I) described herein is form I, form II or form III.
In some embodiments, form I of the present invention is characterized by an X-ray powder diffraction pattern of form I having diffraction peaks at the following 2Θ angles: 6.70 ° ± 0.2 °,7.29 ° ± 0.2 °,11.18 ° ± 0.2 °,19.04 ° ± 0.2 °,27.27 ° ± 0.2 °.
In other embodiments, the invention provides form I, wherein the X-ray powder diffraction pattern of form I has diffraction peaks at the following 2Θ angles: 6.70 ° ± 0.2 °,7.29 ° ± 0.2 °,8.07 ° ± 0.2 °,11.18 ° ± 0.2 °,16.16 ° ± 0.2 °,19.04 ° ± 0.2 °,21.50 ° ± 0.2 °,22.03 ° ± 0.2 °,22.70 ° ± 0.2 °,27.27 ° ± 0.2 °.
In other embodiments, the invention provides form I, wherein the X-ray powder diffraction pattern of form I has diffraction peaks at the following 2Θ angles: 5.69 ° ± 0.2 °,6.70 ° ± 0.2 °,7.29 ° ± 0.2 °,8.07 ° ± 0.2 °,11.18 ° ± 0.2 °,16.16 ° ± 0.2 °,19.04 ° ± 0.2 °,21.50 ° ± 0.2 °,22.03 ° ± 0.2 °,22.70 ° ± 0.2 ° and 27.27 ° ± 0.2 °.
In other embodiments, the invention provides form I, wherein the X-ray powder diffraction pattern of form I has diffraction peaks at the following 2Θ angles: 5.69++0.2°, 6.70++0.2°, 7.29++0.2°, 8.07++0.2°, 11.18++0.2°, 11.67++0.2°, 12.73++0.2°, 13.34++0.2°, 14.48++0.2°, 14.78++0.2°, 15.68++0.2°, 16.16++0.2°, 16.95++0.2°, 17.40++0.2°, 17.93++0.2°, 18.40++0.2°, 19.04++0.2°, 19.24++0.2°, 19.64++0.2°, 20.19++0.2°,21.13 ++0.2°,21.50 ° ± 0.2 °,22.03 ° ± 0.2 °,22.70 ° ± 0.2 °,23.34 ° ± 0.2 °,23.73 ° ± 0.2 °,24.27 ° ± 0.2 °,25.11 ° ± 0.2 °,25.56 ° ± 0.2 °,25.94 ° ± 0.2 °,26.47 ° ± 0.2 °,26.78 ° ± 0.2 °,27.27 ° ± 0.2 °,28.36 ° ± 0.2 °,29.22 ° ± 0.2 °,29.78 ° ± 0.2 °,30.69 ° ± 0.2 °,31.19 ° ± 0.2 °,31.60 ° ± 0.2 °,32.58 ° ± 0.2 °,33.26 ° ± 0.2 ° 33.90 ° ± 0.2 °.
In other embodiments, the invention provides form I, wherein the X-ray powder diffraction pattern of form I has diffraction peaks at the following 2Θ angles: 5.69 ° ± 0.2 °,6.70 ° ± 0.2 °,7.29 ° ± 0.2 °,8.07 ° ± 0.2 °,11.18 ° ± 0.2 °,11.67 ° ± 0.2 °,12.73 ° ± 0.2 °,13.34 ° ± 0.2 °,14.48 ° ± 0.2 °,14.78 ° ± 0.2 °,15.68 ° ± 0.2 °,16.16 ° ± 0.2 °,16.95 ° ± 0.2 °,17.40 ° ± 0.2 °,17.93 ° ± 0.2 °,18.40 ° ± 0.2 °,19.04 ° ± 0.2 °,19.24 ° ± 0.2 °,19.64 ° ± 0.2 °,19.99 ° ± 0.2 °,20.19 ° ± 0.2 °,21.13 ° ± 0.2 °,21.50 ° ± 0.2 °,22.03 ° ± 0.2 °,22.70 ° ± 0.2 °,23.34 ° ± 0.2, and 1.34 ° ± 0.2; 23.73 ° ± 0.2 °,24.27 ° ± 0.2 °,25.11 ° ± 0.2 °,25.56 ° ± 0.2 °,25.94 ° ± 0.2 °,26.47 ° ± 0.2 °,26.78 ° ± 0.2 °,27.27 ° ± 0.2 °,28.36 ° ± 0.2 °,29.22 ° ± 0.2 °,29.78 ° ± 0.2 °,30.69 ° ± 0.2 °,31.19 ° ± 0.2 °,31.60 ° ± 0.2 °,32.58 ° ± 0.2 °,33.26 ° ± 0.2 °,33.90 ° ± 0.2 °,35.50 ° ± 0.2 °,37.57 ° ± 0.2 °,38.11 ° ± 0.2 °,39.60 ° ± 0.2 °,41.83 ° ± 0.2 °,42.91 ° ± 0.2 °,43.96 ° ± 0.2 °,47.03 ° ± 0.2 °.
In some embodiments, form I of the present invention is characterized by having an X-ray powder diffraction pattern substantially as shown in figure 1.
In some embodiments, form I of the present invention is characterized in that the differential scanning calorimetry pattern of form I comprises an endotherm at 251.88 ℃ ± 3 ℃.
In some embodiments, form I of the present invention is characterized by having a differential scanning calorimeter substantially as shown in fig. 2.
In some embodiments, the crystalline form II of the present invention is characterized by an X-ray powder diffraction pattern of crystalline form II having diffraction peaks at the following 2Θ angles: 11.55 °,12.72 °,18.77 °,21.91 °,23.80 °, wherein the diffraction peak has an error margin of ±0.2 °.
In some embodiments, the crystalline form II of the present invention is characterized by an X-ray powder diffraction pattern of crystalline form II having diffraction peaks at the following 2Θ angles: 11.55 °,11.74 °,12.72 °,14.93 °,17.89 °,18.77 °,21.52 °,21.91 °,22.20 °,23.80 °, wherein the diffraction peak has a margin of error of ±0.2 °.
In some embodiments, the crystalline form II of the present invention is characterized by an X-ray powder diffraction pattern of crystalline form II having diffraction peaks at the following 2Θ angles: 7.25 °,9.82 °,10.64 °,11.17 °,11.55 °,11.74 °,12.72 °,14.35 °,14.93 °,15.31 °,15.67 °,17.89 °,18.77 °,19.11 °,19.71 °,20.98 °,21.33 °,21.52 °,21.91 °,22.20 °,22.97 °,23.55 °,23.80 °,24.07 °,24.32 °,24.77 °,25.56 °,25.80 °,26.27 °,26.89 °,27.37 °,27.88 °,28.10 °,28.27 °,28.55 °,28.79 °,29.21 °,30.06 °,30.41 °,30.66 °,30.86 °,31.39 °,31.70 °,32.03 °,32.50 °,33.03 °,33.19 °,33.88 °,34.35 °,35.08 °,35.51 °,35.67 °, wherein the diffraction peaks have an error margin of ±0.2°.
In some embodiments, the crystalline form II of the present invention is characterized by an X-ray powder diffraction pattern of crystalline form II having diffraction peaks at the following 2Θ angles: the diffraction errors of 7.25 °,9.82 °,10.64 °,11.17 °,11.55 °,11.74 °,12.72 °,14.35 °,14.93 °,15.31 °,15.67 °,17.89 °,18.77 °,19.11 °,19.71 °,20.98 °,21.33 °,21.52 °,21.91 °,22.20 °,22.97 °,23.55 °,23.80 °,24.07 °,24.32 °,24.77 °,25.56 °,25.80 °,26.27 °,26.89 °,27.37 °,27.88 °,28.10 °,28.27 °,28.55 °,28.79 °,29.21 °,30.06 °,30.41 °,30.66 °,30.86 °,31.39 °,31.70 °,32.03 °,32.50 °,33.03 °,33.19 °,33.88 °,34.35 °,35.08 °, 45.24 °,35.67 °,37.19 °,38.02 °,38.75 °,39.57 °,40.15 °,40.61 °, 41.67 °, 5425.41.80 °, and ±43.20.43 °.
In some embodiments, form II of the present invention is characterized by having an X-ray powder diffraction pattern substantially as shown in figure 3.
In some embodiments, the crystalline form II of the present invention is characterized in that the differential scanning calorimetry pattern of crystalline form II comprises endothermic peaks at 125.00 ℃ ± 3 ℃ and 255.60 ℃ ± 3 ℃.
In some embodiments, form II of the present invention is characterized by having a differential scanning calorimeter substantially as shown in fig. 4.
In some embodiments, the crystalline form III of the present invention is characterized by an X-ray powder diffraction pattern of crystalline form III having diffraction peaks at the following 2Θ angles: 8.54 °,14.34 °,20.16 °,20.70 °,21.95 °, wherein the diffraction peak has an error margin of ±0.2 °.
In some embodiments, the crystalline form III of the present invention is characterized by an X-ray powder diffraction pattern of crystalline form III having diffraction peaks at the following 2Θ angles: 8.54 °,11.82 °,14.34 °,16.23 °,20.16 °,20.46 °,20.70 °,21.15 °,21.95 °,26.39 °, wherein the diffraction peak has a margin of error of ±0.2 °.
In some embodiments, the crystalline form III of the present invention is characterized by an X-ray powder diffraction pattern of crystalline form III having diffraction peaks at the following 2Θ angles: 7.88 °,8.54 °,11.82 °,12.71 °,14.34 °,14.83 °,15.79 °,16.23 °,16.94 °,19.32 °,20.16 °,20.46 °,20.70 °,21.15 °,21.32 °,21.74 °,21.95 °,22.38 °,22.80 °,23.64 °,24.42 °,24.83 °,25.75 °,26.39 °,26.91 °,27.56 °,27.95 °,29.52 °,29.76 °,30.14 °,30.41 °,31.21 °,31.80 °,32.86 °,33.63 °,34.08 °,34.64 °,35.09 °,36.20 °,36.63 °,37.05 °,37.28 °,39.98 °,40.40 °,40.89 °,41.71 °,43.16 °,44.36 °,44.77 °, wherein the diffraction peaks have an error tolerance of ±0.2 °.
In some embodiments, form III of the present invention, wherein the form III has an X-ray powder diffraction pattern substantially as shown in fig. 5.
In some embodiments, the crystalline form III of the present invention is characterized in that the differential scanning calorimetry pattern of crystalline form III comprises endothermic peaks at 119.04 ℃ ± 3 ℃ and 255.59 ℃ ± 3 ℃.
In some embodiments, form III of the present invention, wherein the form III has a differential scanning calorimeter substantially as shown in fig. 6.
In one aspect, the present invention provides an amorphous form of a compound of formula (I),
wherein the amorphous form has an X-ray powder diffraction pattern substantially as shown in figure 7.
In another aspect, the present invention relates to a pharmaceutical composition comprising a compound of formula (I) or a crystalline form I, a crystalline form II, a crystalline form III, an amorphous form or a combination thereof according to the present invention, and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant or combination thereof.
In some embodiments, the pharmaceutical compositions of the invention further comprise one or more additional active ingredients selected from ACE inhibitors, renin inhibitors, angiotensin II receptor antagonists, beta-receptor blockers, acetylsalicylic acid, diuretics, calcium antagonists, statins, digitalis derivatives, calcium sensitizers, nitrates and antithrombotics.
In one aspect, the invention relates to the use of a compound of formula (I) or a crystalline form I, a crystalline form II, a crystalline form III or an amorphous form thereof or of a pharmaceutical composition thereof for the manufacture of a medicament for the treatment, prevention or alleviation of a disease in a patient: diabetic nephropathy, hyperaldosteronism, hypertension, heart failure, sequelae of myocardial infarction, cirrhosis, renal failure or stroke.
In another aspect, the invention relates to the use of a compound of formula (I) or a crystalline form I, a crystalline form II, a crystalline form III or an amorphous form thereof or of a pharmaceutical composition thereof for the manufacture of a medicament, wherein the medicament is used as a mineralocorticoid receptor antagonist.
In one aspect, the invention relates to a method of preventing, treating or alleviating a disease in a patient, wherein the disease is diabetic nephropathy, hyperaldosteronism, hypertension, heart failure, sequelae of myocardial infarction, cirrhosis, renal failure or stroke; the method comprises administering to a patient a pharmaceutically acceptable effective dose of a compound of formula (I) or any of its crystalline forms or the amorphous form or the pharmaceutical composition of the present invention.
In another aspect, the present invention also relates to a process for the preparation of a compound of formula (I) or a crystalline or amorphous form thereof.
The solvent used in the process for producing the compound of formula (I) or a crystalline form or amorphous form thereof according to the present invention is not particularly limited, and any solvent which dissolves the starting materials to a certain extent and does not affect the properties thereof is included in the present invention. In addition, many similar modifications, equivalent substitutions, or equivalent solvents, combinations of solvents, and different proportions of solvent combinations described herein are considered to be encompassed by the present invention. The present invention gives the preferred solvents to be used in each reaction step.
The preparation experiments of the compound shown in the formula (I) or the crystal form or the amorphous form thereof according to the invention are described in detail in the examples section. Meanwhile, the invention provides an activity test experiment (such as a pharmacokinetics experiment), a solubility experiment, a stability experiment, a hygroscopicity experiment and the like of the crystal form. Experiments prove that the crystal form, particularly the crystal form I, has better bioactivity, better solubility and higher stability, and is suitable for pharmaceutical use.
In addition, according to the result of the hygroscopicity experiment, the crystal form I is not easy to be deliquesced due to the influence of high humidity, and the long-term storage and placement of the medicine are facilitated.
Definitions and general terms
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All patents and publications referred to herein are incorporated by reference in their entirety. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are described herein.
"crystalline form" or "crystalline form" refers to a solid having a highly regular chemical structure, including, but not limited to, single or multicomponent crystals, and/or polymorphs, solvates, hydrates, clathrates, co-crystals, salts, solvates of salts, hydrates of salts of the compounds. The crystalline form of a substance may be obtained by a number of methods known in the art. Such methods include, but are not limited to, melt crystallization, melt cooling, solvent crystallization, crystallization in a defined space, e.g., in a nanopore or capillary, crystallization on a surface or template, e.g., on a polymer, crystallization in the presence of additives such as co-crystallizing anti-molecules, desolvation, dehydration, rapid evaporation, rapid cooling, slow cooling, vapor diffusion, sublimation, reactive crystallization, anti-solvent addition, milling, solvent drop milling, and the like.
"solvent" refers to a substance (typically a liquid) that is capable of completely or partially dissolving another substance (typically a solid). Solvents useful in the practice of the present invention include, but are not limited to, water, acetic acid, acetone, acetonitrile, benzene, chloroform, carbon tetrachloride, methylene chloride, dimethyl sulfoxide, 1, 4-dioxane, ethanol, ethyl acetate, butanol, tertiary butanol, N-dimethylacetamide, N-dimethylformamide, formamide, formic acid, heptane, hexane, isopropanol, methanol, methyl ethyl ketone, mesitylene, nitromethane, polyethylene glycol, propanol, pyridine, tetrahydrofuran, toluene, xylene, mixtures thereof, and the like.
"solvate" means a compound having a solvent on, in, or on and in the crystal lattice that can be water, acetic acid, acetone, acetonitrile, benzene, chloroform, carbon tetrachloride, methylene chloride, dimethyl sulfoxide, 1, 4-dioxane, ethanol, ethyl acetate, butanol, t-butanol, N-dimethylacetamide, N-dimethylformamide, formamide, formic acid, heptane, hexane, isopropanol, methanol, methyl ethyl ketone, methyl pyrrolidone, mesitylene, nitromethane, polyethylene glycol, propanol, pyridine, tetrahydrofuran, toluene, xylene, mixtures thereof, and the like. A specific example of a solvate is a hydrate, wherein the solvent on the surface, in the crystal lattice or both is water. The hydrate may or may not have other solvents than water on the surface of the substance, in the crystal lattice, or both.
The crystalline forms may be identified by a variety of techniques such as X-ray powder diffraction (XRPD), infrared absorption spectroscopy (IR), melting point, differential Scanning Calorimetry (DSC), thermogravimetric analysis (TGA), nuclear magnetic resonance, raman spectroscopy, X-ray single crystal diffraction, dissolution calorimetry, scanning Electron Microscopy (SEM), quantitative analysis, solubility and dissolution rate, and the like.
The X-ray powder diffraction (XRPD) can detect the information of crystal form change, crystallinity, crystal structure state and the like, and is a common means for identifying the crystal form. The peak positions of the XRPD patterns are largely dependent on the structure of the crystalline form, relatively insensitive to experimental details, and their relative peak heights depend on many factors related to sample preparation and instrument geometry. Thus, in some embodiments, the crystalline forms of the invention are characterized by XRPD patterns having certain peak positions, substantially as shown in the XRPD patterns provided in the figures of the invention. Meanwhile, the measure of 2θ of the XRPD pattern may have experimental errors, and the measure of 2θ of the XRPD pattern may slightly differ from instrument to instrument and sample to sample, so the value of 2θ cannot be regarded as absolute. Depending on the instrument conditions used in this test, diffraction peaks have a margin of error of + -0.2 deg..
Differential Scanning Calorimeter (DSC) is a method for measuring the temperature of a sample and an inert reference substance (commonly used alpha-Al) by continuously heating or cooling under the control of a program 2 O 3 ) A technique in which the energy difference between them varies with temperature. The endothermic peak height of the DSC curve depends on many factors related to sample preparation and instrument geometry, while peak position is relatively insensitive to experimental details. Thus, in some embodiments, the crystalline forms of the invention are characterized by a DSC profile with characteristic peak positions substantially as shown in the DSC profile provided in the accompanying figures of the invention. Meanwhile, the DSC profile may have experimental errors, and the peak position and peak value of the DSC profile may slightly differ from instrument to instrument and from sample to sample, so that the peak position or the value of the DSC endothermic peak cannot be regarded as absolute. Depending on the instrument conditions used in this test, there is an error margin of + -3deg.C for the endothermic peak.
In the context of the present invention, the 2 theta values in the X-ray powder diffraction pattern are all in degrees (°).
The term "substantially as shown in the figures" means that at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or at least 95%, or at least 99% of the peaks in the X-ray powder diffraction pattern or DSC pattern or raman spectrum or infrared spectrum are shown in its figure.
When referring to a spectrogram or/and data appearing in the graph, a "peak" refers to a feature that one skilled in the art can recognize that is not attributable to background noise.
The present invention relates to novel crystalline forms of a compound of formula (I), e.g., forms I, II or III, which exist in substantially pure crystalline form.
By "substantially pure" is meant that one form is substantially free of the other form or forms, i.e., the purity of the form is at least 80%, or at least 85%, or at least 90%, or at least 93%, or at least 95%, or at least 98%, or at least 99%, or at least 99.5%, or at least 99.6%, or at least 99.7%, or at least 99.8%, or at least 99.9%, or the form contains less than 20%, or less than 10%, or less than 5%, or less than 3%, or less than 1%, or less than 0.5%, or less than 0.1%, or less than 0.01% of the total volume or total weight of the forms.
By "substantially free" is meant that the percentage of one or more other crystalline forms in the total volume or weight of the crystalline forms is less than 20%, or less than 10%, or less than 5%, or less than 4%, or less than 3%, or less than 2%, or less than 1%, or less than 0.5%, or less than 0.1%, or less than 0.01%.
"relative intensity" (or "relative peak height") in an XRPD pattern refers to the ratio of the intensity of the first intensity peak to the intensity of the first intensity peak in all diffraction peaks of the X-ray powder diffraction pattern (XRPD) at 100%.
In the context of the present invention, when used or whether or not the word "about" or "about" is used, means within 10%, suitably within 5%, particularly within 1% of a given value or range. Alternatively, the term "about" or "approximately" means within an acceptable standard error of the average value to one of ordinary skill in the art. Whenever a number is disclosed having a value of N, any number within the values of N+/-1%, N+/-2%, N+/-3%, N+/-5%, N+/-7%, N+/-8% or N+/-10% will be explicitly disclosed, where "+/-" means plus or minus.
"room temperature" in the present invention means a temperature from about 10℃to about 40 ℃. In some embodiments, "room temperature" refers to a temperature from about 20 ℃ to about 30 ℃; in other embodiments, "room temperature" refers to 20 ℃,22.5 ℃,25 ℃,27.5 ℃, and so forth.
The invention relates to a compound shown in formula (I) or a crystal form or amorphous composition, a preparation, administration and application thereof
The pharmaceutical compositions of the present invention are characterized by comprising a compound of formula (I) or a crystalline or amorphous and pharmaceutically acceptable carrier, adjuvant, or vehicle thereof. The amount of the compound or crystalline or amorphous form thereof in the pharmaceutical compositions of the present invention is effective to detectably treat or ameliorate mineralocorticoid-related disorders in a patient.
As described herein, the pharmaceutically acceptable compositions of the present invention further comprise a pharmaceutically acceptable carrier, adjuvant, or vehicle, as used herein, including any solvents, diluents, or other liquid excipients, dispersing or suspending agents, surfactants, isotonic agents, thickening agents, emulsifying agents, preservatives, solid binders or lubricants, and the like, suitable for the particular target dosage form. As described in the following documents: in Remington, the Science and Practice of Pharmacy,21st edition,2005,ed.D.B.Troy,Lippincott Williams&Wilkins,Philadelphia,and Encyclopedia of Pharmaceutical Technology,eds.J.Swarbrick and J.C.Boylan,1988-1999,Marcel Dekker,New York, in combination with the teachings of the present document, shows that different carriers can be used In the preparation of pharmaceutically acceptable compositions and their well-known methods of preparation. In addition to any conventional carrier vehicle that is incompatible with the compounds of the present invention or crystalline or amorphous forms thereof, such as any adverse biological effects produced or interactions with any other component of the pharmaceutically acceptable composition in a deleterious manner, their use is also contemplated by the present invention.
Materials that can be used as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers; aluminum; aluminum stearate; lecithin; serum proteins, such as human serum proteins; buffer substances such as phosphates; glycine; sorbic acid; potassium sorbate; a partial glyceride mixture of saturated vegetable fatty acids; water; salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts; colloidal silicon; magnesium trisilicate; polyvinylpyrrolidone; polyacrylate; a wax; polyethylene-polyoxypropylene-block polymers; lanolin; sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; a gum powder; malt; gelatin; talc powder; adjuvants such as cocoa butter and suppository waxes; oils such as peanut oil, cotton seed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycol compounds such as propylene glycol and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic salt; ringer's solution; ethanol; phosphate buffer solution; and other non-toxic suitable lubricants such as sodium lauryl sulfate and magnesium stearate; a colorant; a release agent; coating the clothing material; a sweetener; a flavoring agent; a perfume; preservatives and antioxidants.
The pharmaceutical compositions of the present invention may be in the form of capsules, tablets, pills, powders, granules and aqueous suspensions or solutions; the administration may be by the following route: oral administration, injection, spray inhalation, topical administration, rectal administration, nasal administration, buccal administration, vaginal administration or administration via an implantable drug cassette.
Oral administration may be in the form of: tablets, pills, capsules, dispersible powders, granules or suspensions, syrups, elixirs and the like; administration by topical means may be by the following forms: ointments, gels, medicated plasters, and the like.
The compound of formula (I) or a crystalline or amorphous form thereof according to the present invention is preferably formulated as a dosage unit form to reduce the amount and uniformity of administration. The term "dosage unit form" as used herein refers to physically discrete units of medicament for the patient for the appropriate treatment. However, it will be appreciated that the daily total usage of the compounds of formula (I) of the present invention or crystalline or amorphous forms thereof, or the pharmaceutical compositions of the present invention, will be determined by the attending physician according to the sound judgment of the medical scope. The particular effective dosage level for any particular patient or organism will depend upon a number of factors including the particular compound or crystalline or amorphous form thereof being treated and the severity of the condition being treated, the particular composition being used, the age, weight, health, sex and dietary habits of the patient, the time of administration, the route of administration and rate of excretion of the particular compound or crystalline or amorphous form thereof being used, the duration of the treatment, the application of the drug to a combination or combination with specific compounds or crystalline or amorphous forms thereof, and other factors well known in the pharmaceutical arts.
The effective dose of the active ingredient used may vary with the compound used or its crystalline or amorphous form, the mode of administration and the severity of the condition to be treated. However, generally, satisfactory results are obtained when the compounds of the invention or crystalline or amorphous forms thereof are administered at a dosage of about 0.25-1000mg/kg animal body weight per day, preferably at 2-4 divided doses per day, or in a slow release form. For most large mammals, the total daily dosage is about 1 to 100mg/kg, preferably about 2 to 80mg/kg, of the active compound or crystalline or amorphous form thereof. Dosage forms suitable for oral administration comprising about 0.25 to 500mg of the active compound or crystalline or amorphous form thereof intimately admixed with a solid or liquid pharmaceutically acceptable carrier. This dosage regimen can be adjusted to provide the optimal therapeutic response. In addition, separate doses may be administered several times per day, or the doses may be proportionally reduced, depending on the condition being treated.
The compounds of the present invention or crystalline or amorphous forms thereof, pharmaceutical compositions of the present invention are useful in conditions suitable for the prevention and/or treatment of various disorders and diseases associated therewith, particularly disorders characterized by elevated plasma aldosterone concentrations or by changes in plasma aldosterone concentrations relative to plasma renin concentrations, or disorders associated with such changes. Examples which may be mentioned are: spontaneous primary aldosteronism, aldosteronism associated with adrenal hyperplasia, adrenal adenoma and/or carcinoma, aldosteronism associated with cirrhosis, aldosteronism associated with heart failure, and (relative) aldosteronism associated with primary hypertension, etc.
In particular, the compounds of the present invention or crystalline or amorphous forms thereof are useful for the treatment or prevention of: diabetic nephropathy, hyperaldosteronism, hypertension, heart failure, sequelae of myocardial infarction, cirrhosis, renal failure or stroke.
Drawings
Fig. 1 is an X-ray powder diffraction (XRPD) pattern of crystalline form I of the compound of formula (I).
FIG. 2 is a Differential Scanning Calorimeter (DSC) of form I of a compound of formula (I).
Fig. 3 is an X-ray powder diffraction (XRPD) pattern of form II of the compound of formula (I).
FIG. 4 is a Differential Scanning Calorimeter (DSC) of form II of a compound of formula (I).
Fig. 5 is an X-ray powder diffraction (XRPD) pattern of crystalline form III of the compound of formula (I).
FIG. 6 is a Differential Scanning Calorimeter (DSC) of crystalline form III of a compound of formula (I).
FIG. 7 is an amorphous X-ray powder diffraction (XRPD) pattern of a compound of formula (I).
FIG. 8 is an X-ray powder diffraction (XRPD) pattern of the compound of formula (I) prepared according to example 1.
Detailed Description
The invention is further illustrated by way of examples which are not intended to limit the scope of the invention.
The X-ray powder diffraction analysis method used in the invention comprises the following steps: an Empyrean diffractometer was used to obtain X-ray powder diffraction patterns using Cu-K alpha radiation (45 KV,40 mA). The powdered sample was prepared as a thin layer on a monocrystalline silicon sample holder, placed on a rotating sample stage and analyzed in steps of 0.0167 ° in the range of 3 ° -60 °. Data was collected using Data Collector software, highScore Plus software processed the Data, and Data Viewer software read the Data.
The Differential Scanning Calorimeter (DSC) analysis method used in the invention comprises the following steps: differential scanning calorimeter was performed using a TA Q2000 module with a thermal analysis controller. Data were collected and analyzed using TA Instruments Thermal Solutions software. About 1-5mg of the sample was accurately weighed into a specially made aluminum crucible with a lid, and sample analysis was performed from room temperature to about 300 ℃ using a linear heating device of 10 ℃/min. During use, the DSC cell was purged with dry nitrogen.
The thermal weight loss (TGA) analysis method used in the invention comprises the following steps: thermal weightlessness was performed using a TA Q500 module with a thermal analysis controller. Data were collected and analyzed using TA Instruments Thermal Solutions software. About 10mg of the sample was accurately weighed into a platinum sample pan and sample analysis was performed from room temperature to about 300 ℃ using a linear heating device at 10 ℃/min. During use, the TGA furnace chamber was purged with dry nitrogen.
The humidity absorption performance of the invention is measured by a DVS INT-Std dynamic moisture and gas adsorption analyzer of the company Surface Measurement Systems, british, and the humidity test range is as follows: 0% -95%, airflow: 200mL/min, temperature: 25 ℃, test point: one test point was taken per liter of 5% humidity.
Detailed description of the preferred embodiments
Specific synthetic methods of the compound of formula (Ia), i.e. 4- (4-cyano-2-methoxyphenyl) -5-cyclobutyloxy-2, 8-dimethyl-1, 4-dihydro-1, 6-naphthyridine-3-carboxamide, are described in example 7 of international application WO 2019223629 A1.
Examples
Example 1 (S) -4- (4-cyano-2-methoxyphenyl) -5-cyclobutyloxy-2, 8-dimethyl-1, 4-dihydro-1, 6-naphthyridine-3-carboxamide (Compound of formula (I))
4- (4-cyano-2-methoxyphenyl) -5-cyclobutoxy-2, 8-dimethyl-1, 4-dihydro-1, 6-naphthyridine-3-carboxamide (4.0 g) was weighed, methanol, acetonitrile and formic acid (57 mL total) were added to dissolve the sample, and supercritical fluid chromatography (instrument: waters SFC; column: large xylonite AD-H column 10 mm. Times.250 mm 5um; conditions: isocratic gradient, 30% MeOH+70% CO) was used 2 The method comprises the steps of carrying out a first treatment on the surface of the Flow rate: 8mL/min; column temperature: 35 ℃; back pressure: 100bar; chiral resolution was performed at 10 μl per sample injection to give a white solid (1.76 g, 44.0%) with HPLC purity: 99.53%, ee value: 99.93%.
Identified by Empyrean X-ray powder diffraction (XRPD) analysis: using Cu-K alpha radiation, the resulting white solid product had an X-ray powder diffraction pattern as shown in FIG. 8.
MS(ESI,pos.ion)m/z:405.2(M+1).
1 H NMR(400MHz,CDCl 3 )δ(ppm)7.63(s,1H),7.29(d,J＝7.9Hz,1H),7.15(dd,J＝7.9,1.2Hz,1H),7.08(s,1H),6.51(s,1H),5.78(s,1H),5.44(s,1H),5.24–4.86(m,2H),3.99(s,3H),2.50(s,3H),2.45–2.34(m,1H),2.24–2.16(m,1H),2.14(s,3H),2.01–1.89(m,1H),1.72–1.52(m,3H).
EXAMPLE 2 Crystal form I of the present invention
1. Preparation of form I
The compound (52 mg) represented by the formula (I) produced as described in example 1 was added to acetonitrile (1.0 mL), stirred at room temperature until the solid was dissolved, slowly added dropwise with water (2.0 mL), gradually precipitated, stirred continuously for crystallization for 5 hours, suction-filtered, and the cake was washed with water (1.0 mL. Times.2), and then dried in vacuo at room temperature for 6 hours to give a white solid (23 mg, 44.23%).
2. Identification of form I
(1) Identified by Empyrean X-ray powder diffraction (XRPD) analysis: using Cu-ka radiation, there are the following diffraction peaks expressed in degrees 2θ:5.69 °,6.70 °,7.29 °,8.07 °,11.18 °,11.67 °,12.73 °,13.34 °,14.48 °,14.78 °,15.68 °,16.16 °,16.95 °,17.40 °,17.93 °,18.40 °,19.04 °,19.24 °,19.64 °,19.99 °,20.19 °,21.13 °,21.50 °,22.03 °,22.70 °,23.34 °,23.73 °,24.27 °,25.11 °,25.56 °,25.94 °,26.47 °,26.78 °,27.27 °,28.36 °,29.22 °,29.78 °,30.69 °,31.19 °,31.60 °,32.58 °,33.26 °,33.90 °,35.50 °,37.57 °,38.11 °,39.60 °,41.83 °,42.91 °,43.96 °, and 47.03 °, with error tolerances of ±0.2 °.
In particular, form I of the present invention has an X-ray powder diffraction pattern substantially as shown in figure 1.
(2) Identification by TA Q2000 Differential Scanning Calorimeter (DSC) analysis: the scan rate was 10deg.C/min, including an endothermic peak at 251.88deg.C, with an error margin of + -3deg.C. In particular, form I of the present invention has a differential scanning calorimetric diagram substantially as shown in fig. 2.
EXAMPLE 3 Crystal form II of the present invention
1. Preparation of form II
The compound (50 mg) of the formula (I) produced by the method of example 1 was added to acetone (1.0 mL), stirred at room temperature until the solid dissolved, followed by rapid precipitation of the solid, stirred overnight, suction filtered, and the filter cake was washed with acetone (0.5 mL. Times.2), and then dried in vacuo at room temperature for 5 hours to give a white solid (28 mg, 56.00%).
2. Identification of form II
(1) Identified by Empyrean X-ray powder diffraction (XRPD) analysis: using Cu-ka radiation, there are the following diffraction peaks expressed in degrees 2θ:7.25 °,9.82 °,10.64 °,11.17 °,11.55 °,11.74 °,12.72 °,14.35 °,14.93 °,15.31 °,15.67 °,17.89 °,18.77 °,19.11 °,19.71 °,20.98 °,21.33 °,21.52 °,21.91 °,22.20 °,22.97 °,23.55 °,23.80 °,24.07 °,24.32 °,24.77 °,25.56 °,25.80 °,26.27 °,26.89 °,27.37 °,27.88 °,28.10 °,28.27 °,28.55 °,28.79 °,29.21 °,30.06 °,30.41 °,30.66 °,30.86 °,31.39 °,31.70 °,32.03 °,32.50 °,33.03 °,33.19 °, 33.57 °,34.35 °,35.08 °,35.51 °,35.67 °, 37.19.02 °,38.75 °,39.57 °,40.15 °,40.61 °, 37.38 °, 37.24.37.38 °, and 46344.45 °, and margin values of 2.39.38 °, 37.38 °,45 °, and 35.38.38 °, and 35.98 °, and 32.35 °, and 32 °, and 35.35 °, and 35.39.35 °, and 35 °, and are present. In particular, form II of the present invention has an X-ray powder diffraction pattern substantially as shown in figure 3.
(2) Identification by TA Q2000 Differential Scanning Calorimeter (DSC) analysis: the scan rate was 10deg.C/min, including endothermic peaks at 125.00℃and 255.60 ℃with a margin of error of + -3 ℃. In particular, form II of the present invention has a differential scanning calorimetric diagram substantially as shown in fig. 4.
EXAMPLE 4 Crystal form III of the present invention
1. Preparation of form III
The method comprises the following steps:
the compound (52 mg) shown in the formula (I) prepared according to the method of the example 1 is added into ethyl acetate (2.0 mL), the temperature is heated to 77 ℃, the heating is closed after the solid is dissolved, the reaction is naturally cooled to the room temperature, n-heptane (1.0 mL) is slowly added dropwise, the solid is gradually separated out, and the stirring crystallization is continued for 2 hours; suction filtration, filter cake washing with n-heptane (1.0 mL. Times.2) followed by vacuum drying at room temperature for 5 hours afforded a white solid (35 mg, 67.31%).
The second method is as follows:
the compound (49 mg) represented by the formula (I) produced by the method of example 1 was added to ethanol (1.0 mL), stirred at room temperature until the solid was dissolved, n-heptane (2.0 mL) was slowly added dropwise, gradually solid precipitation was continued, stirred and crystallized for 5 hours, suction filtration was performed, and the cake was washed with n-heptane (1.0 mL. Times.2), and then dried at room temperature under vacuum overnight to give a white solid (19 mg, 38.78%).
And a third method:
the compound (50 mg) represented by the formula (I) produced by the method of example 1 was added to ethyl formate (1.0 mL), the solid was dissolved by stirring at room temperature, n-heptane (1.0 mL) was slowly added dropwise, the solid was gradually precipitated, stirring crystallization was continued for 5 hours, suction filtration was performed, the cake was washed with n-heptane (1.0 mL. Times.2), and then dried under vacuum at room temperature overnight to give a white solid (28 mg, 56.00%).
2. Identification of form III
(1) Identified by Empyrean X-ray powder diffraction (XRPD) analysis: using Cu-ka radiation, there are the following diffraction peaks expressed in degrees 2θ:7.88 °,8.54 °,11.82 °,12.71 °,14.34 °,14.83 °,15.79 °,16.23 °,16.94 °,19.32 °,20.16 °,20.46 °,20.70 °,21.15 °,21.32 °,21.74 °,21.95 °,22.38 °,22.80 °,23.64 °,24.42 °,24.83 °,25.75 °,26.39 °,26.91 °,27.56 °,27.95 °,29.52 °,29.76 °,30.14 °,30.41 °,31.21 °,31.80 °,32.86 °,33.63 °,34.08 °,34.64 °,35.09 °,36.20 °,36.63 °,37.05 °,37.28 °,39.98 °,40.40 °,40.89 °,41.71 °,43.16 °,44.36 °, and 44.77 ° have error margins of ±0.2 °. In particular, form III of the present invention has an X-ray powder diffraction pattern substantially as shown in figure 5.
(2) Identification by TA Q2000 Differential Scanning Calorimeter (DSC) analysis: the scan rate was 10 ℃/min, including endothermic peaks at 119.04 ℃ and 255.59 ℃, with a margin of error of + -3 ℃. In particular, form III of the present invention has a differential scanning calorimetric diagram substantially as shown in fig. 6.
EXAMPLE 5 amorphous forms according to the invention
1. Amorphous preparation
The compound (50 mg) of the formula (I) produced as described in example 1 was added to ethanol (4.0 mL), stirred at room temperature until the solid was dissolved, the filtrate was filtered to give a clear solution, the solvent was removed by rotary evaporation of the solution, and a pale yellow solid (37 mg, 74.00%) was obtained by collection.
2. Amorphous characterization
Identified by Empyrean X-ray powder diffraction (XRPD) analysis: using Cu-ka radiation, the pale yellow solid had an X-ray powder diffraction pattern as shown in fig. 7, and was amorphous.
EXAMPLE 6 pharmacokinetic experiments
The compound shown in the formula (I) or the crystal form or the amorphous form thereof are respectively filled into capsules for oral administration.
8-12kg male Beagle dogs were divided into 2 groups of 3, each group was orally administered with 5mg/kg of capsules containing the test sample, and blood was collected at time points 0.25,0.5,1.0,2.0,4.0,6.0,8.0 and 24 hours. A standard curve of a suitable range is established according to the sample concentration, the concentration of the test sample in the plasma sample is determined in MRM mode using the AB SCIEX API4000 type LC-MS/MS, and quantitative analysis is performed. According to the drug concentration-time curve, the pharmacokinetic parameters were calculated using the WinNonLin 6.3 software non-compartmental model method. The experimental results are shown in table 1.
TABLE 1 pharmacokinetic experimental data for the crystalline forms of the invention
| Sample for sample | T max (h) | C max (ng/ml) | AUC last (h*ng/ml) |
| Example 2 | 3.17 | 2030 | 6110 |
Conclusion of experiment:
as can be seen from table 1, the crystal form I of the present invention has a larger exposure in beagle dogs and better pharmacokinetic properties.
Example 7 stability experiment
(1)High temperature experiments: and (3) placing a proper amount of sample to be tested into a flat weighing bottle, spreading the sample into a thin layer with the thickness of less than or equal to 5mm, standing the thin layer at the temperature of 40+/-2 ℃ and/or 60+/-2 ℃ for 30 days, sampling at the 5 th, 10 th and 30 th days, detecting according to stability key investigation projects, observing the color change of the sample, and detecting the purity of the sample by HPLC.
(2)High humidity experiment: placing a batch of samples into flat weighing bottle, spreading into thin layer with thickness less than or equal to 5mm, standing at 25deg.C under RH 90% + -5% for 30 days, sampling at 5 th, 10 th and 30 th days, and examining the items according to stabilityAnd (5) detecting, namely observing color change of the sample, and detecting the purity of the sample by HPLC.
(3)Illumination test: placing a batch of test sample into flat weighing bottle, spreading into thin layer with thickness less than or equal to 5mm, placing into illumination box (with ultraviolet lamp), and placing the sample into illumination box with illuminance of 4500+ -500 lx and ultraviolet light of more than or equal to 0.7w/m 2 Is left for 30 days, is sampled on days 5, 10 and 30, is observed for color change, and is checked for purity by HPLC.
(4)Accelerated experiments: taking a batch of samples, packaging with a single-layer PE (polyethylene) package and an aluminum foil package, standing for 6 months under the condition of 40+/-2 ℃/75+/-5% RH, sampling at 1, 2, 3 and 6 months, observing the color change of the samples, detecting the purity of the samples by HPLC (high performance liquid chromatography), and testing the moisture by TGA (thermal gel electrophoresis).
Conclusion of experiment:
under the conditions of high temperature (60 ℃), high humidity (25 ℃, RH 90% +/-5%) and illumination, the appearance and purity of the crystal form I are not obviously changed; under the condition of acceleration experiment, the appearance, purity and water content of the crystal form I are not obviously changed.
In conclusion, the crystal form I has better stability under various lofting conditions and is suitable for pharmaceutical use.
Example 8 hygroscopicity test
The moisture absorption of a test sample (i.e., the compound of the present invention or a crystalline or amorphous form thereof) is measured by a dynamic moisture absorption instrument.
Conclusion: the crystal forms are not easy to be affected by high humidity and deliquesced.
The above description is merely a basic description of the inventive concept, and any equivalent transformation according to the technical solution of the present invention shall fall within the protection scope of the present invention.
In the description of the present specification, a description referring to terms "one embodiment," "some embodiments," "examples," "specific examples," or "some examples," etc., means that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the present invention. In this specification, schematic representations of the above terms are not necessarily directed to the same embodiment or example.
While embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and not to be construed as limiting the invention, and that variations, modifications, alternatives and variations may be made to the above embodiments by one of ordinary skill in the art within the scope of the invention.
Claims (11)
1. A crystalline form I of a compound of formula (I), characterized in that the X-ray powder diffraction pattern of form I has diffraction peaks at the following 2Θ angles: 6.70 ° ± 0.2 °,7.29 ° ± 0.2 °,11.18 ° ± 0.2 °,19.04 ° ± 0.2 °,27.27 ° ± 0.2 °;
2. form I according to claim 1, characterized in that the X-ray powder diffraction pattern of form I has diffraction peaks at the following 2Θ angles: 6.70 ° ± 0.2 °,7.29 ° ± 0.2 °,8.07 ° ± 0.2 °,11.18 ° ± 0.2 °,16.16 ° ± 0.2 °,19.04 ° ± 0.2 °,21.50 ° ± 0.2 °,22.03 ° ± 0.2 °,22.70 ° ± 0.2 °,27.27 ° ± 0.2 °.
3. Form I according to claim 1 or 2, characterized in that the X-ray powder diffraction pattern of form I has diffraction peaks at the following 2Θ angles: 5.69++0.2°, 6.70++0.2°, 7.29++0.2°, 8.07++0.2°, 11.18++0.2°, 11.67++0.2°, 12.73++0.2°, 13.34++0.2°, 14.48++0.2°, 14.78++0.2°, 15.68++0.2°, 16.16++0.2°, 16.95++0.2°, 17.40++0.2°, 17.93++0.2°, 18.40++0.2°, 19.04++0.2°, 19.24++0.2°, 19.64++0.2°, 20.19++0.2°,21.13 ++0.2°,21.50 ° ± 0.2 °,22.03 ° ± 0.2 °,22.70 ° ± 0.2 °,23.34 ° ± 0.2 °,23.73 ° ± 0.2 °,24.27 ° ± 0.2 °,25.11 ° ± 0.2 °,25.56 ° ± 0.2 °,25.94 ° ± 0.2 °,26.47 ° ± 0.2 °,26.78 ° ± 0.2 °,27.27 ° ± 0.2 °,28.36 ° ± 0.2 °,29.22 ° ± 0.2 °,29.78 ° ± 0.2 °,30.69 ° ± 0.2 °,31.19 ° ± 0.2 °,31.60 ° ± 0.2 °,32.58 ° ± 0.2 °,33.26 ° ± 0.2 ° 33.90 ° ± 0.2 °.
4. Form I according to claim 1 or 2, characterized in that it has an X-ray powder diffraction pattern substantially as shown in figure 1.
5. Form I of claim 1 or 2, characterized in that the differential scanning calorimetry pattern of form I comprises an endotherm at 251.88 ℃ ± 3 ℃.
6. Form I of claim 5, having a differential scanning calorimeter substantially as shown in fig. 2.
7. A pharmaceutical composition comprising the crystalline form I of any one of claims 1-6, and a pharmaceutically acceptable carrier, excipient, adjuvant, or combination thereof.
8. The pharmaceutical composition of claim 7, wherein the excipient is a diluent.
9. The pharmaceutical composition according to claim 7 or 8, further comprising one or more additional active ingredients selected from ACE inhibitors, renin inhibitors, angiotensin II receptor antagonists, beta-receptor blockers, acetylsalicylic acid, diuretics, calcium antagonists, statins, calcium sensitizers and antithrombotics.
10. Use of the crystalline form I of any one of claims 1-6 or the pharmaceutical composition of any one of claims 7-9 for the manufacture of a medicament for treating, preventing or alleviating a disease in a patient comprising: diabetic nephropathy, hyperaldosteronism, hypertension, heart failure, sequelae of myocardial infarction, cirrhosis, renal failure or stroke.
11. Use of the crystalline form I of any one of claims 1-6 or the pharmaceutical composition of any one of claims 7-9 in the manufacture of a medicament, wherein the medicament is used as a mineralocorticoid receptor antagonist.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010331846 | 2020-04-24 | ||
| CN2020103318469 | 2020-04-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113549066A CN113549066A (en) | 2021-10-26 |
| CN113549066B true CN113549066B (en) | 2023-07-21 |
Family
ID=78101901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110440945.5A Active CN113549066B (en) | 2020-04-24 | 2021-04-23 | Crystal forms of dihydronaphthyridine compounds and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN113549066B (en) |
| WO (1) | WO2021213486A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007009670A1 (en) * | 2005-07-22 | 2007-01-25 | Bayer Healthcare Ag | 4-chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof |
| WO2009056934A1 (en) * | 2007-10-31 | 2009-05-07 | Pfizer Products Inc. | 1,4-dihydronaphthyridine derivatives |
| CN101641352A (en) * | 2007-02-27 | 2010-02-03 | 拜耳先灵制药股份公司 | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof |
| CN110511219A (en) * | 2018-05-22 | 2019-11-29 | 广东东阳光药业有限公司 | The dihydronaphthridine class compound and application thereof that phenyl replaces |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102006026583A1 (en) * | 2006-06-07 | 2007-12-13 | Bayer Healthcare Aktiengesellschaft | Aryl-substituted hetero-bicyclic compounds and their use |
-
2021
- 2021-04-23 WO PCT/CN2021/089149 patent/WO2021213486A1/en active Application Filing
- 2021-04-23 CN CN202110440945.5A patent/CN113549066B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007009670A1 (en) * | 2005-07-22 | 2007-01-25 | Bayer Healthcare Ag | 4-chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof |
| CN101641352A (en) * | 2007-02-27 | 2010-02-03 | 拜耳先灵制药股份公司 | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof |
| WO2009056934A1 (en) * | 2007-10-31 | 2009-05-07 | Pfizer Products Inc. | 1,4-dihydronaphthyridine derivatives |
| CN110511219A (en) * | 2018-05-22 | 2019-11-29 | 广东东阳光药业有限公司 | The dihydronaphthridine class compound and application thereof that phenyl replaces |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021213486A1 (en) | 2021-10-28 |
| CN113549066A (en) | 2021-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110577536B (en) | Salts of benzoylaminopyridine derivatives and their use in medicine | |
| CN110577534B (en) | Salts of benzoylaminopyridine derivatives and their use in medicine | |
| CN110577538B (en) | Salts of benzoylaminopyridine derivatives and their use in medicine | |
| CN110577540B (en) | Salts of benzoylaminopyridine derivatives and their use in medicine | |
| CN110577533A (en) | Salts of benzoylaminopyridine derivatives and their use in medicine | |
| CN110577541A (en) | Salts of benzoylaminopyridine derivatives and their use in medicine | |
| CN110577539A (en) | Salts of benzoylaminopyridine derivatives and their use in medicine | |
| JP2023505116A (en) | Crystal forms of tricyclic nitrogen-containing compounds and uses thereof | |
| CN111269177B (en) | Crystal forms of quinolinone compounds | |
| CN113549067B (en) | Crystal forms of dihydronaphthyridine compounds and application thereof | |
| CN112079837B (en) | Salts of dihydropyrimidine derivatives and their use in medicine | |
| CN111269178A (en) | Crystal forms of quinolinone compounds | |
| CN113549066B (en) | Crystal forms of dihydronaphthyridine compounds and application thereof | |
| CN111269176A (en) | Crystal forms of quinolinone compounds | |
| TW202327593A (en) | Polymorph of kras inhibitor and preparation method for polymorph and use thereof | |
| CN115141132B (en) | Crystal forms of pyrrole amide compound, preparation method and application thereof | |
| CN115010662B (en) | Crystal forms of quinolinone compounds and application thereof | |
| CN114573589B (en) | Salts, complexes of dihydropyrimidine derivatives and their use in medicine | |
| US20240376051A1 (en) | Crystalline form of pyrrole amide compound, preparation method therefor and use thereof | |
| CN112851640B (en) | Sulfate of pyrimidine benzamide compound and application thereof | |
| CN112851641B (en) | Hydrochloride of pyrimidine benzamide compound and application thereof | |
| CN114685431B (en) | Crystalline form of axitinib citrate | |
| CN112851643B (en) | Hydrochloride of pyrimidine benzamide compound and application thereof | |
| CN117417327A (en) | Salt of HCV inhibitor, crystalline form of salt, pharmaceutical composition thereof and use thereof | |
| CN118239932A (en) | Co-crystals of triazine derivatives, pharmaceutical compositions thereof and their use in medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20211231 Address after: 519000 room 105-73504, No. 6, Baohua Road, Hengqin new area, Zhuhai City, Guangdong Province (centralized office area) Applicant after: Nianyan Pharmaceutical (Zhuhai) Co.,Ltd. Address before: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province Applicant before: SUNSHINE LAKE PHARMA Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |